0156T0 — HL Genomics Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for HL Genomics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS
Standards:	IFRS	IFRS	IFRS
Status:	Final	Final	Final
Revenue
Total Revenue	24,811	28,167	28,877
Cost of Revenue
Gross Profit	9,424	11,230	12,536
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	17,144	19,212	19,549
Operating Profit	7,667	8,954	9,328
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Other Net Non Operating Costs
Net Income Before Taxes	9,115	10,438	10,544
Provision for Income Taxes
Net Income After Taxes	7,158	8,415	8,452
Net Income Before Extraordinary Items
Net Income	7,158	8,415	8,452
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	7,158	8,415	8,452
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	920	1,081	1,086
Dividends per Share